MARKET

PLX

PLX

Protalix Biother
AMEX

Real-time Quotes | Nasdaq Last Sale

1.095
+0.035
+3.30%
Opening 15:16 05/25 EDT
OPEN
1.060
PREV CLOSE
1.060
HIGH
1.110
LOW
1.060
VOLUME
298.35K
TURNOVER
150.13K
52 WEEK HIGH
3.081
52 WEEK LOW
0.7000
MARKET CAP
51.53M
P/E (TTM)
-2.0402
1D
5D
1M
3M
1Y
5Y
PLX: First Quarter Financial and Operational Review
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 1Q:22 financial and operational results in a May 16, 2022 press release and filing of Form 10-Q . The materials were followed by a ...
Zacks Small Cap Research · 05/17 10:13
Protalix BioTherapeutics GAAP EPS of -$0.05, revenue of $16.09M
Protalix BioTherapeutics press release (NYSE:PLX): Q1 GAAP EPS of -$0.05. Revenue of $16.09M (+42.1% Y/Y). CEO comment: "The announcement of compelling results from both the BRIGHT and BALANCE phase III trials
Seekingalpha · 05/16 10:53
BRIEF-Protalix Biotherapeutics Reports Q1 Loss Of 5 Cents Per Share
reuters.com · 05/16 10:53
Protalix BioTherapeutics Q1 EPS $(0.05) Up From $(0.14) YoY, Sales $16.09M Beat $15.50M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.05) per share. This is a 64.29 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales
Benzinga · 05/16 10:51
Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein ex...
PR Newswire · 05/16 10:50
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 05/16 09:18
-- Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q1 Revenue $16.1M
MT Newswires · 05/16 07:07
Notable earnings before Monday's open
BITF, CGEN, CLSN, CMRX, OTCQB:CVSI, GOED, KALA, LTRY, LUNA, MNMD, NOVN, OEG, PLX, PTE, SOHU, SSYS, SYN, SYRS, TCRT, WEJO, WIX, WRBY For Seeking Alpha's full earnings season calendar, click
Seekingalpha · 05/13 14:29
More
No Data
Learn about the latest financial forecast of PLX. Analyze the recent business situations of Protalix Biother through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PLX stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
High11.00
Average11.00
Low11.00
Current 1.095
EPS
Actual
Estimate
-0.20-0.15-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 32
Institutional Holdings: 12.41M
% Owned: 26.37%
Shares Outstanding: 47.06M
TypeInstitutionsShares
Increased
6
1.51M
New
7
1.67M
Decreased
3
89.21K
Sold Out
9
231.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.94%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
Non-Executive Chairman/Independent Director
Zeev Bronfeld
President/Chief Executive Officer/Director
Dror Bashan
Chief Financial Officer/Senior Vice President/Treasurer/Secretary
Eyal Rubin
Senior Vice President
Einat Almon
Vice President - Research & Development
Yael Hayon
Independent Director
Amos Bar-Shalev
Independent Director
Pol Boudes
Independent Director
David Granot
Independent Director
Gwen Melincoff
Independent Director
Aharon Schwartz
No Data
No Data
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Webull offers kinds of Protalix Biotherapeutics Inc stock information, including AMEX:PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.